Patent Attorneys
Attorneys-at-Law
Patent Mapping and Patent Families
– Case Studies
Background
Information is required in order to…
• allow for good patent prosecution
•
•
•
•
provide a basis for portfolio development
watch competitors’ patent portfolio
react to inquiries
help in M&A projects
What is Patent Mapping?
Patent Mapping…
• is a tool for assessing large sets of patent data
• allows the creation of a visual representation of
information from and about patent documents in
a way that is easy to understand
• can identify which technical fields particular
applicants are active in, and how their filing
patterns and IP portfolios change over time
• helps to find out which countries are particularly
active in certain technical fields
Who Uses Patent Mapping?
Patent Mapping can provide valuable information for…
•
•
•
•
•
corporate decision-makers
investors (venture capitalists, promotional banks)
innovators (R&D)
influencers (patent offices, policy-makers)
management
How is a Patent Map created?
Gathering of Information:
• define the data to be included in the analysis
• choose a database that covers the required
information
• define your query
• collect data
• remove “noise” (irrelevant or insufficient
information)
• fine-tune results, e.g., harmonize applicants' names
How is a Patent Map created?
Quantitative Analysis
 statistically analyzing patent information
 typically useful data comes from bibliographical
information (e.g., number of patent applications,
assignees, inventors, or patent classification
codes, etc
 examples:
- number-based analysis
- time-based analysis
- ranking analysis
How is a Patent Map created?
Qualitative Analysis
 analyzing the content of patent applications/
patents
 analysis can be performed by inter-relating
technology contents, patent classification codes,
assignees, application dates (e.g., selecting a core
patent)
How is a Patent Map created?
Quantitative
Analysis
Qualitative
Analysis
Patent
Map
How is a Patent Map created?
Analyzing of Information:
• carry out a statistical analysis of structured
information (bibliographic data, inventors, titles, …)
• do text mining on unstructured information such as
abstracts
• export data to a spreadsheet / database
• define the purpose of analysis (technologies,
application, …)
• add categories of information to documents
• run a statistical analysis
• check results
How is a Patent Map created?
Visualizing Results:
• visualize results of statistical analysis by creating a
patent map
• there are many different kinds of patent maps for
various purposes and users
• various graphs can be used to show the results of
statistical analysis
Example Patent Maps
Source: MaxVal IP
Case Studies – Example 1
Starbucks’ Coffee Cup Sleeve U.S. Patent 5,205,473
Case Studies – Example 1
Source: IPVision, Inc.
Case Studies – Example 2
Car Airbag Chip U.S. Patent 5,345,824
Case Studies – Example 2
Source: IPVision, Inc.
Case Studies – Example 2
Source: IPVision, Inc.
Case Studies – Example 3
Diaper U.S. Patents 4,704,116 and 4,695,278
Case Studies – Example 3
Source: IPVision, Inc.
Case Studies – Example 4
Monoclonal antibodies for detection/treatment of cancer
number of records filed during 2000 to 2005: >3000
number of records considered for mapping: 127
basis for selection of patent records: Assignees with
more than15 patent records
Data provided by Lakshmikumaran (India)
Case Studies – Example 4
Assignee Distribution
IBC Pharm aceuticals (2)
Ceptyr (15)
Im m unom edics Inc. (19)
Corixa Corporation (23)
Roche Holding (34)
CuraGen Corporation (38)
Case Studies – Example 4
IP Activities
Activity
Ceptyr
Corixa
Corporation
Immunomedics
Inc.
Antagonist of PR092240
Roche
Holding
6
6
Induces cell death
2
1
Antagonist of STOP-1
1
Binding to human VEGF
2
Modulates immune response
18
14
8
7
1
4
Inhibition of HGF receptor
activation
30
2
2
3
2
Binds to NCA90 or NCA95
1
Inhibition of cancer cell
proliferation
Modulates cell cycle
IBC
Pharmaceuticals
1
Binding to specific
Antigen/polypeptide
Modulates apoptosis
CuraGen
Corporation
3
10
2
9
1
Case Studies – Example 4
Mode of Treatment
12 + 1 + 3
4+3
43 + 24 + 11
4 + 33 + 4
1
2
Prophylactic
Therapeutic
Detection
*Color codes: Main/ independent claim; dependent claim, disclosed
Case Studies – Example 4
Number of Applications vs. Mode
of Treatment and Assignee
17
13
No. of records
30
1
4
25
13
1
5
2
13
5
1
5
2
Corixa Corporation
Immunomedics Inc.
IBC Pharmaceuticals
er
ap
e
ut
ic
n
Th
D
et
ec
t io
hy
hy
la
la
ct
ct
ic
ic
/T
he
Th
ra
er
pe
ap
ut
eu
ic
tic
/D
et
ec
tio
n
ro
p
ro
p
n/
P
P
et
ec
tio
ut
ic
/D
er
ap
e
2
CuraGen Corporation
1
0
Th
Roche Holding
Ceptyr
1
15
10
7
2
1
30
20
15
Mode of treatment
Case Studies – Example 4
Number of Applications vs.
Type of Cancer and Assignee
16
10
12
5
1 9
4
2
6
4
3
1
13
3
2
2
2
3
2
2
5
1
1
1 7
4
2
1
1
2
1
1
Roche Holding
Corixa Corporation
1
3
1
1
Immunomedics Inc.
CuraGen Corporation
Ceptyr
2
IBC Pharmaceuticals
sp
ce
r(
un
C
an
3
6
ec
if
B
ra ied
)
in
B
re tum
as
o
tc r
a
Lu
n
ng ce
r
O
va c a
n
ri
ce
P
an a n
r
ca
cr
nc
ea
er
tic
c
an
C
ol
on cer
ca
K
id
ne nce
r
y
P
c
ro
st a nc
at
er
e
ca
Ly nc
m er
ph
o
Le ma
B
la uke
dd
m
ia
er
Th
ca
yr
nc
oi
er
d
ca
nc
er
No. of records
16
14
12
10
8
6
4
2
0
5
3
Type of cancer
fla
m
m
y
at
or
di
se
a
A
A se
ut
rt
hr
oi
m
it
I
s
m
ch is
u
C Inf ne em
a r ec
d
t di i a
C iov iou sea
el
l c as s d se
is
yc cu
le lar eas
ab di
e
no s e
A rm ase
G
th
P
C
er a lit
e l CR
os ie
ls
X
cl s
ig - a
er
na ss
os
l m oc
D
is
i
N
i
O od at e ab
VX ul
d et e
a
t
as io dis s
so n or
ci di de
at so r
ed rd
di er
so
rd
C
er
e
L
eb es r
ra io
l e ns
de
m
a
In
No. of records
Case Studies – Example 4
Number of Applications vs.
Kind of Disease and Assignee
29
30
25
10
5
2
15
3
5
4
1
1
2
1
4
1
14
2
2
3
2
Other diseases
29
29
12
3
1
0
14
14
CuraGen Corporation
20
Ceptyr
2
IBC Pharmaceuticals
2
Immunomedics Inc.
1
Roche Holding
Corixa Corporation
Case Studies – Example 4
Number of Applications vs.
Priority Year and Assignee
29
30
25
4
20
CuraGen Corporation
1
14
5
3
2
5
3
3
3
2
1
Roche Holding
1
5
15
1
2
8
3
10
3
1
5
1
2
10
Corixa Corporation
1
1
3
2
Immunomedics Inc.
IBC Pharmaceuticals
Priority year
P
rio
r
to
19
94
19
94
19
95
19
96
19
97
19
98
19
99
20
00
20
01
20
02
2
Ceptyr
0
20
03
No. of records
3
7
Case Studies – Example 4
Number of Applications for a particular
Assignee vs. Primary IPC Code
50
45
No. of records
40
35
48
30
43
25
20
15
20
10
5
1
1
2
6
9
0
A01K
C12P
C07H
C12Q
G01N
Primary IPC code
A61K
C07K
C12N
Case Studies – Example 4
Number of Applications vs.
Primary IPC Code and Assignee
25
12
1
CuraGen Corporation
14
1
8
No. of records
25
4
1
20
1
1
3
2
8
1
10
1
1
2
1
4
4
5
1
3
0
1K
A0
2P
C1
7H
C0
2Q
C1
1
G0
N
1K
A6
Primary IPC code
7K
C0
2N
C1
Roche Holding
Corixa Corporation
1
7
5
IBC Pharmaceuticals
11
6
15
1
Ceptyr
Immunomedics, Inc.
Case Studies – Example 4
108 105
77
82
90
53
Country
PC AU
T
Ap
pl
.
US
CA
EP
17
JP
14
IL
13
BR
8
CN
7
CZ
7
DE
X
M
AT
6
4
3
DK
3
ZA
3
NO
2
NZ
1
BG
1
G
B
1
PL
1
TR
1
O
A
1
EA
120
110
100
90
80
70
60
50
40
30
20
10
0
ES
No. of records
Number of Applications of a
particular Assignee vs. Country
Case Studies – Example 4
35
31
37
4
5
3 6
1
5
2
DK
ZA
2
4
3
1
3
1
NO
NZ
2
40
3
2
BG
GB
30
1
1
PL
20
1
TR
OA
1
1
1
EA
ES
10
tyr
Cep
orat
i
ixa
Co r
p
Cor
por
atio
n
Cor
aG e
n
on
0
Cur
DE
AT
MX
7
5
1
old i
ng
2
he H
BR
CN
CZ
1
1
Roc
1
IL
9
I nc.
JP
9
9
12
4
1
10
12
14
di cs
2
EP
10
tica
ls
2
16
14
uno
me
11
10
13
ceu
2
19
Number of Applications vs.
Country and Assignee
14
Imm
24
13
1
US
CA
19
rma
2
PCT Appl
AU
15
15 23
Pha
15
14
29
26
24
24
IBC
24
Patent Attorneys
Attorneys-at-Law
Thank you!